MEI Pharma, Inc. (LITS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
LITS Chart
MEI Pharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RS Richard Slavik Newbridge Financial Services Group Inc. | 1,999 | $13,153.42 | $1,479.26 | -$11,674.16 | -88.75% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $4.64 | $2.96 | -$1.68 | -36.21% |
MEI Pharma, Inc. (LITS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MEI Pharma, Inc. ever had a stock split?
MEI Pharma, Inc. Profile
| Capital Markets Industry | Financials Sector | Justin J. File CEO | NASDAQ (NMS) Exchange | 55279B301 CUSIP |
| US Country | 4 Employees | 16 Nov 2023 Last Dividend | 17 Apr 2023 Last Split | - IPO Date |
Overview
Lite Strategy, Inc. is a clinical-stage pharmaceutical company specializing in the development of innovative and unique therapies aimed at treating cancer. Originally founded in 2000 as MEI Pharma, Inc., the company underwent a rebranding in September 2025, adopting its current name, Lite Strategy, Inc. Headquartered in San Diego, California, the company is dedicated to advancing cancer treatment through research and the development of groundbreaking drug candidates.
Products and Services
- Novel Cancer Therapies
Lite Strategy, Inc. focuses on creating innovative therapies that target cancer cells through unique mechanisms of action. This includes the development of compounds that aim to improve patient outcomes and quality of life.
- Differentiated Treatment Modalities
The company is invested in producing differentiated treatment modalities that set its offerings apart from traditional therapies. This could involve combination therapies, personalized medicine approaches, or therapies addressing specific cancer subtypes.
- Clinical Trials and Development
Lite Strategy actively conducts clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are a crucial part of the drug development process and are designed to ensure that new treatments meet regulatory standards and offer substantial benefits to patients.
- Regulatory Expertise
The company offers services related to navigating complex regulatory environments. Their team possesses extensive knowledge of the pharmaceutical regulations, aiding in the successful approval of their investigational therapeutics through various regulatory bodies.
- Collaborative Partnerships
Lite Strategy collaborates with other biotech and pharmaceutical companies, academic institutions, and research organizations to bolster its research capabilities and expand its pipeline of therapeutics. These partnerships can enhance resource sharing and innovation in treatment development.
